Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc has shown promising results in its Phase 2 Proof of Concept study for RAP-219, demonstrating significant reductions in both long episodes and clinical seizure frequency among patients, contributing to enhanced daily functioning and overall treatment tolerability. The company's ongoing research into its RAP technology platform, which includes investigational therapies for chronic pain and hearing disorders, further positions it to leverage an expanding market driven by favorable trends in physician sentiment and reimbursement dynamics for new medications. Overall, the positive clinical outcomes and enthusiasm from healthcare providers signal a compelling potential for Rapport Therapeutics to make an impactful entry into the therapeutic market for neurological and psychiatric disorders.

Bears say

Rapport Therapeutics faces significant risks that cast a negative outlook on its stock, primarily due to the uncertainty surrounding the clinical success of its pipeline products, including RAP-219, which may also contend with competition from more advanced therapies in the market. The company is also likely to encounter commercial adoption challenges and potential delays in drug development related to manufacturing risks, further exacerbating its financial stability and outlook. Furthermore, Rapport's dependence on additional funding to advance its pipeline programs could indicate vulnerabilities in its financial position, complicating its ability to navigate the highly competitive landscape of neurological and psychiatric disorder treatments.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.